Transplant News and Research

RSS

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

New therapeutic strategy improves superior renal function after kidney transplantation

Researchers at Charité - Universitätsmedizin Berlin, together with 16 other transplant centers in Germany and Switzerland successfully tested a new therapeutic strategy that allows for superior renal function after kidney transplantation. The results were published online in the journal "The Lancet".

1 Mar 2011

San Diego Hospice is California's first provider of unique children care program

The Comprehensive Care Management Programs at San Diego Hospice celebrates one year as California's first provider of Partners for Children. This unique state-funded program allows chronically ill children on Medi-Cal and CCS to receive pain and symptom management services, or palliative care, at home.

1 Mar 2011

Genzyme introduces new global grant program to support LSD patient community

Genzyme Corporation today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards.

28 Feb 2011

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and CellSeed Inc., a Japanese biotechnology firm, have entered into a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine, "Cell Sheet Engineering," LA BioMed President and CEO David I. Meyer, PhD, announced today.

28 Feb 2011

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Omni Bio Pharmaceutical, Inc., an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

28 Feb 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Kidney transplant proposal - younger patients greater success

Soon kidney transplant recipients would be younger under a proposal being considered by the nation’s organ transplant network. This would replace the current ‘first-come-first-served’ system and is intended to provide better matches between the life expectancies of recipients and the functional life of donated kidneys.

27 Feb 2011

Harvard Bioscience fourth quarter revenues increase 6.8% to $1.9 million

Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial highlights for the fourth quarter and full year ended December 31, 2010.

From Harvard Bioscience 25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

High radiation doses can increase risk of cancer in dialysis patients

High radiation doses put a significant number of dialysis patients at increased risk of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

25 Feb 2011

Refrigerated whole blood may have shelf life beyond current standard of 24 to 48 hours

In a finding that may potentially improve survival from war injuries and disasters, laboratory researchers report that refrigerated whole blood may have a shelf life well beyond the current standard of 24 to 48 hours.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Human umbilical cord blood-derived EPCs accelerate wound healing in diabetics

Transplanting human umbilical cord blood-derived endothelial progenitor cells (EPCs) has been found to "significantly accelerate" wound closure in diabetic mouse models, said a team of Korean researchers publishing in the current issue of Cell Transplantation.

23 Feb 2011

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

W. L. Gore & Associates announced the GORE PROPATEN Vascular Graft for hemodialysis access has received CE Mark. Arteriovenous Grafts are used to create a conduit for repeated blood access during hemodialysis, allowing blood to be withdrawn from the body and cleansed when a patient has End Stage Renal Disease, commonly referred to as kidney failure.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Transplant News and Research

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Mathematical model predicts lifespan of stem cells

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

New therapeutic strategy improves superior renal function after kidney transplantation

San Diego Hospice is California's first provider of unique children care program

Genzyme introduces new global grant program to support LSD patient community

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Kidney transplant proposal - younger patients greater success

Harvard Bioscience fourth quarter revenues increase 6.8% to $1.9 million

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

High radiation doses can increase risk of cancer in dialysis patients

Refrigerated whole blood may have shelf life beyond current standard of 24 to 48 hours

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

MD Anderson physician honored for impact on blood, marrow transplantation

Human umbilical cord blood-derived EPCs accelerate wound healing in diabetics

GORE PROPATEN Vascular Graft for hemodialysis access receives CE Mark approval

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News